Double negative T cell therapy - Ruichuang Biotechnology
Alternative Names: DNTsLatest Information Update: 03 Feb 2021
At a glance
- Originator Ruichuang Biotechnology
- Class Antineoplastics; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Acute myeloid leukaemia